Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
Mar 27, 2023

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration...

Mar 21, 2023

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

Jan 10, 2023

Serum and cerebrospinal fluid samples from the Phase 3 study of NurOwn® in ALS to be donated to the NEALS biorepository for use by the research community NEW YORK, Jan. 10, 2023 /PRNewswire/ --...

View All

Events
Thursday, March 30, 2023
8:00am - 9:00am EDT

Participant Numbers:
Toll Free: 877 545 0523
International: 973 528 0016
Entry Code: 943129

Replay Numbers:
Toll Free: 877 481 4010
International: 919 882 2331
Replay Passcode:  47908

Press Release

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds